project id: TCGA-BLCA; case submitter id: TCGA-DK-AA77; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.87; rna integrity number: 10.0; age at index: 61; days to birth: -22365; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1952; age at diagnosis: 22365; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 618.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2013; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 168; initial weight: 950.0; sample id: d9b66125-cf32-4928-9488-8efb146684f9; sample submitter id: TCGA-DK-AA77-01A; portion id: cc15173e-ebfc-437f-aa68-07ffd8a9e2ec; portion submitter id: TCGA-DK-AA77-01A-11; slide id: 26caf5cb-cc4f-4522-bd2b-343fb70205fe; slide submitter id: TCGA-DK-AA77-01A-01-TSA; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 75.0; section location: TOP;